Thermalin Diabetes is picking up steam – and funding – as it develops a more concentrated and faster-acting version of insulin. The Boston and Cleveland-based company just raised $5.9 million from private investors in the first tranche of a Series B round. To date, it has raised about $15 million in equity and $8 million in NIH […]
Everyone likes to talk about funding for digital health – Y Combinator is doing biotech now! Andreesen Horowitz gets into health tech! Deals and dollars look great in Q1 2014! It’s not as easy to make cheery slide decks about funding for the rest of the healthcare startup world: pharma, medical devices and bio tech […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Thanks to a new three-year, $1 million grant, a group of researchers at Case Western Reserve University are continuing to develop and test a form of glucose-responsive insulin that may someday be able to reduce the risk of dangerous hypoglycemic episodes in people with type 1 diabetes. The insulin is being developed in the lab […]
Next-generation insulin developer Thermalin Diabetes has received a $4.5 million grant from the National Institutes of Health to continue development of its insulin analogs. The grant is expected to fund Cleveland-based Thermalin through the filing of an investigational new drug (IND) application for a rapid-acting insulin analog drug candidate, CEO Rick Berenson said. “We are […]
Next-generation insulin developer Thermalin Diabetes is targeting an $8 million series B round of investment that would fund the first in-human studies of its insulin analogs. A successful clinical trial — though a long way off for the Cleveland-based company — would represent a huge milestone for Thermalin. CEO Rick Berenson said a positive trial […]
Next-generation insulin developer Thermalin Diabetes has closed a $2.85 million Series A investment round. The Cleveland-based startup plans to use the funding to step up production of its insulin analogs — new proteins engineered to act like insulin in the body — and continue preclinical testing. The insulin analogs are heat resistant, unlike the natural […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Rick Berenson is charged with developing the business of one of Northeast Ohio's most promising startups -- Thermalin Diabetes, which is developing new forms of insulin called "insulin analogs." The company is offering diabetes without the insulin side effects: it will last longer and have less cancer risk.
Thermalin Diabetes Inc. has been granted by Case Western Reserve University an exclusive license for a portfolio of insulin analogs, proteins engineered to act like insulin in the body.
Startup Thermalin Diabetes Inc. has raised $1.9 million in equity to commercialize new forms of insulin developed at Case Western Reserve University, according to a regulatory filing.
Thermalin Diabetes Inc., the Cleveland start-up that is developing new forms of insulin, has received a $250,000 investment commitment from JumpStart Ventures on the way to a Series A fundraising likely to be completed by the end of May. “It’s the first piece of what I think will be close to $2 million-worth of financing […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Case Western Reserve University and University Hospitals Case Medical Center will participate in a consortium of national experts investigating why unexplained anemia is common in older adults. The consortium, called the Partnership for Anemia: Clinical and Translational Trials in the Elderly, is the result of a $16 million grant awarded by the National Institute on Aging.